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Abstract
Background: Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of
chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects are
reported, with the major two being bleeding and ibrutinib-related atrial fibrillation. Atrial fibrillation pathogenesis in
this setting is not completely clear, and no prospective studies have evaluated the impact of previous cardiologic
history and baseline characteristics.
Methods: We prospectively performed cardiologic assessment in 43 CLL patients before starting ibrutinib therapy.
Cardiologic workup included comorbidity collection and electrocardiographic and echocardiographic baseline evaluation.
Results: After a median observation of 8 months, seven patients developed atrial fibrillation (16.3%). Cases
developing atrial fibrillation were all elderly males (p = 0.04), and mostly with a history of previous arterial
hypertension (p = 0.009). Atrial fibrillation occurrence also correlated with the presence of one or more
pre-existent cardiologic comorbidities (p = 0.03), with a higher atrial fibrillation risk score (calculated with
comorbidities and cardiologic risk factor evaluation p < 0.001), and with higher left atrial diameter (p = 0.02) and
area (p = 0.03) by echocardiography. The occurrence of atrial fibrillation was managed after an integrated
cardio-oncologic evaluation: anticoagulation was started in 4 (57.1%) patients and beta-blockers or amiodarone in
5 (71.4%). One patient underwent electric cardioversion and another patient pacemaker positioning to normalise
heart rate in order to continue ibrutinib.
Conclusion: Our data show that echocardiography is a highly informative and reproducible tool that should be
included in pre-treatment workup for patients who are candidates for ibrutinib therapy.
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To the Editor,
Ibrutinib is an oral inhibitor of Bruton’s tyrosine kin-
ase indicated for chronic lymphocytic leukaemia (CLL)
treatment [1]. Most common side effects are bleeding
and ibrutinib-related atrial fibrillation (IRAF) [2, 3].
IRAF pathogenesis is still unclear, and a direct drug ef-
fect on myocardiocyte signalling has been postulated [4].
Various real-life cohorts have been retrospectively re-
ported, focusing on ibrutinib-related adverse event
management [5, 6]. A retrospective study on a large
population of CLL patients revealed an association of AF
risk with older age, male sex, valvular heart disease, and
hypertension [7]. However, no prospective ad hoc studies
are available. We systematically analysed predictors of
IRAF in 43 CLL patients treated with ibrutinib, focusing
on comorbidities, electrocardiographic features (12-deriv-
ation electrocardiography (ECG), 24-h ECG monitoring in
selected case), and trans-thoracic echocardiography
(TTE). Framingham Heart Study and Shanafelt risk score
for AF were also calculated for each patient
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Patients’ clinical and biological characteristics to-
gether with baseline cardiologic comorbidities are pre-
sented in Table 1 (Additional file 1: Supplementary
results). Previous paroxysmal AF was reported in 5
patients, but in none of them was detectable at the
time of cardiologic evaluation nor in the previous
6 months. AF-risk score individuated 8 patients at
low, 18 at intermediate low, 6 at intermediate high,
and 11 at high risk. Twenty-three patients were tak-
ing cardio-active therapy, 13 were under antiplatelets,
and 4 under anticoagulant therapy at the time of en-
rolment. ECG and ECG-Holter analysis did not dis-
play any remarkable alterations (Additional file 1:
Table S1). TTE demonstrated left atrial (LA) diameter
and area over the 75° percentile in 16 and 30% of pa-
tients, respectively, although with preserved function.
Median observation period was of 8 months (range
1–37). AF occurred in 7 patients (16.3%) after a me-
dian of 6 months (range 1–20) from the beginning of
ibrutinib. In 5 patients (71%), IRAF developed within
6 months, whereas it occurred within the first year in
the other two. AF severity was G2 in 4 patients, G3
in 2, and G1 in 1 only. IRAF cases were all elderly
pre-treated males in advanced stage, and one of them
had previous history of AF and 6 (85.7%) had arterial
hypertension. IRAF incidence significantly correlated
with male gender (p = 0.04) and history of arterial
hypertension (p = 0.009). On the whole, IRAF occurred in
25% of the 28 patients with one or more pre-existent car-
diologic comorbidities, whereas incidence was 0 in those
without (N = 15, p = 0.03; Additional file 1: Table S2).
Of note, a high AF-risk score was detected in 86% of
patients who developed IRAF versus 14% in those
who did not (p < 0.001, Fig. 1, upper panel). No
correlation was found with basal ECG evaluation,
whereas TTE data showed a significant association
with IRAF incidence; IRAF cases displayed higher LA
diameter (p = 0.02) and area (p = 0.03; Fig. 1, lower
panel) compared to the others. The occurrence of AF
was managed with anticoagulation in four (57.1%) pa-
tients, and anti-arrhythmic drugs in five (71.4%). Only
one patient underwent electric cardioversion. As
regards new onset of arterial hypertension, we ob-
served four events (3 grade III, 1 grade II) after a me-
dian of 4.8 months (range 1–27). All four cases were
managed with therapy modification, without ibrutinib
discontinuation.
In this prospective analysis, we firstly show that
baseline echocardiographic characteristics signifi-
cantly predict IRAF occurrence. We describe a higher
incidence of IRAF compared to previous reports,
possibly due to closer cardiologic evaluation. Accord-
ingly, methods for IRAF screening were not detailed
in previous studies, with possible underestimation
[8]. In the Shanafelt series, only 72 out of 2444 pa-
tients were treated with ibrutinib and only 2 of them
developed IRAF. As a matter of fact, this score is
more predictive of AF in CLL general population
than of IRAF. However, Shanafelt risk score signifi-
cantly predicted IRAF development in our study,
indicating high reproducibility. As regards echocardi-
ography, in our series, TTE-measured LA linear di-
mensions and area clearly correlated with higher IRAF
incidence, pointing out that it may be a useful and
non-invasive tool to assess IRAF risk in ibrutinib candi-
dates. Finally, similarly to previous experiences, only
half of IRAF cases received anticoagulation because of
both high bleeding risk and possible drug interactions
[5, 7, 9]. In conclusion, TTE is a highly reproducible,
widespread, and low-cost procedure that might be
easily included in the pre-treatment workup of ibrutinib
candidates, and self-interpreted by a skilled
haematologist.
Table 1 Baseline characteristics
N (%)
Age years 72 (51–86)
Gender F14 (32) M29 (68)
Follow-up months 8 (1–37)
STAGE Rai I/II 23 (53)
Rai III/IV 20 (47)
Binet A/B 26 (60)
Binet C 17 (40)
FISH del13 13 (30)
trisomy 12 3 (7)
del17p or TP53 mut 12 (28)
del11q 5 (12)
VHIG Mutated 10/36 (28)
Unmutated 26/36 (72)
Treatment First-line 12 (28)
≥Second line 31 (72)
Cardiovascular
comorbidities
Previous AF 5 (12)
AH 23 (53)
Valvular heart disease 20 (47)
CAD 8 (19)
PAD 4 (9)
Diabetes 4 (9)
Hypothyroidism 5 (12)
Dislipidaemia 12 (28)
Smoke 1 (2)
BMI > 25 7 (16)
Values are given as median (range) or as N (%). AH arterial hypertension, CAD
coronary artery disease, PAD peripheral artery disease, BMI body mass index
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Fig. 1 Upper panel: AF risk score according to IRAF incidence. AF risk score was calculated on age, gender, arterial hypertension, and valvular
heart disease (Shanafelt et al.). Percentages of patients developing or not developing IRAF are shown divided into four risk categories. IRAF cases
were mainly in the high risk group (≥ 5 RF), p < 0.001. AF atrial fibrillation. IRAF ibrutinib-related atrial fibrillation. RF risk factors. Lower panel: main
echocardiographic characteristics associated with IRAF. LA diameter, area, and volume were increased in IRAF patients compared to the others,
significantly for the former two parameters (p = 0.02 and p = 0.03, respectively). LA left atrium, IRAF ibrutinib-related atrial fibrillation
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